Repligen (NASDAQ:RGEN) Director Karen Dawes Sells 275 Shares

Repligen Corporation (NASDAQ:RGEN) Director Karen Dawes sold 275 shares of Repligen stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director owned 91,821 shares in the company, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Repligen Price Performance

RGEN stock traded up $0.80 during trading hours on Thursday, hitting $157.72. 748,695 shares of the stock traded hands, compared to its average volume of 812,802. The stock has a 50-day simple moving average of $156.57 and a 200 day simple moving average of $135.38. The company has a market cap of $8.88 billion, a P/E ratio of 7,889.94, a P/E/G ratio of 3.56 and a beta of 1.11. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. Repligen had a net margin of 0.25% and a return on equity of 4.66%. The company had revenue of $188.81 million during the quarter, compared to the consensus estimate of $181.23 million. During the same period in the prior year, the company earned $0.43 EPS. Repligen’s revenue was up 21.9% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Equities analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current year.

Institutional Trading of Repligen

A number of hedge funds have recently made changes to their positions in the stock. Twin Tree Management LP purchased a new position in Repligen during the first quarter valued at approximately $29,000. Measured Wealth Private Client Group LLC acquired a new stake in shares of Repligen during the 3rd quarter valued at $29,000. Hantz Financial Services Inc. boosted its stake in shares of Repligen by 2,663.6% during the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 293 shares during the period. CWM LLC grew its holdings in shares of Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 135 shares in the last quarter. Finally, Center for Financial Planning Inc. increased its stake in shares of Repligen by 34.2% in the second quarter. Center for Financial Planning Inc. now owns 494 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 126 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. HC Wainwright restated a “buy” rating and issued a $180.00 target price on shares of Repligen in a report on Wednesday, September 3rd. Royal Bank Of Canada reissued an “outperform” rating and issued a $205.00 price target on shares of Repligen in a research note on Tuesday, September 2nd. Barclays upped their price objective on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday. Weiss Ratings reissued a “sell (d+)” rating on shares of Repligen in a research report on Monday. Finally, Hsbc Global Res upgraded shares of Repligen to a “strong-buy” rating in a report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $177.92.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.